

Legislative Update

NCI Council of Research Advocates

Holly Aprea Gibbons, MPP

Maureen Clark Szemborski, MPH

Office of Government and Congressional Relations

■ **FY23 Appropriations**

- And other provisions (permitting reform, FDA user fees reauthorization)

■ **Other Legislation & Issues to Watch**

- ARPA-H Authorization
- CHIPS and Science Act, Inflation Reduction Act
- SBIR/STTR Reauthorization

■ **Recent Briefings & Events**

FY2023 Appropriations (pending)

	FY2022 Enacted	FY2023 House Committee Passed	FY2023 Senate Draft
NCI	\$6.91 B +353 M	\$7.38 B +466 M	\$7.20 B +\$290 M
NIH	\$45.2 B	\$47.7 B +2.5 B	\$48.2 B +\$3.0 B
ARPA-H	\$1.0 B	\$2.75 B	\$1.0 B

Stopgap Funding Expected Until After Midterms (December 16th)

Issues to Resolve:

- Defense versus Non-Defense Funding Levels (“parity”)
- Immigration, Border Security, Abortion Policy Issues
- Emergency aid to Ukraine

HOW NCI RECEIVES ITS FUNDING

NCI receives its funding, or appropriation, from Congress as part of the overall federal budget process.



STEP 1

The White House Office of Management & Budget (OMB) coordinates with federal agencies to formulate the President's Budget, which covers all federal agencies, including the National Cancer Institute (NCI) and National Institutes of Health (NIH), and reflects the President's priorities. The President submits the budget to Congress, which must pass appropriations legislation that funds federal agencies.



STEP 2

The Congressional appropriations committees consider the President's Budget as they prepare appropriations legislation for the next fiscal year.



STEP 3

The appropriations committees finalize their legislative proposals, and the House and Senate consider the proposed legislation. Once passed and reconciled into a unified bill, Congress sends the legislation to the President.



STEP 4

The President signs the appropriations bill into law, making funds available to executive agencies, including NCI and NIH.

NCI Professional Judgment Authority


The National Cancer Act of 1971 gives the NCI Director special authority to submit an annual professional judgment budget directly to the President for review and delivery to Congress. This budget reflects NCI cancer research priorities and identifies areas of potential investment in cancer research.


ARPA-H Authorization Pending

- \$1B appropriation in FY22
- April 2022: Sec. Becerra transfers ARPA-H to NIH
- May 2022: Acting Deputy Director appointed, Adam Russell, D.Phil.
- September 12, 2022: Inaugural Director appointed, Renee Wegrzyn, PhD
- Authorizing legislation (?)



 Both chambers in session

 Senate only in session

 House committee work only / Senate in session

October

Sun.	Mon.	Tues.	Wed.	Thurs.	Fri.	Sat.
						1
2	3	4 Yom Kippur (begins)	5 Yom Kippur (ends)	6	7	8
9	10 Columbus Day	11	12	13	14	15
16	17	18	19	20	21	22
23	24	25	26	27	28	29
30	31					

November


Sun.	Mon.	Tues.	Wed.	Thurs.	Fri.	Sat.
		1	2	3	4	5
6	7	8 	9	10	11 Veterans Day	12
13	14	15	16	17	18	19
20	21	22	23	24 Thanksgiving Day	25	26
27	28	29	30			

December

Sun.	Mon.	Tues.	Wed.	Thurs.	Fri.	Sat.
				1	2	3
4	5	6	7	8	9	10
11	12	13	14	15	16 	17
18	19 Hanukkah (begins)	20	21	22	23	24
25 Christmas Day	26 Xmas (observed) Hanukkah (ends)	27	28	29	30	31

Sources: Office of House Majority Leader Steny H. Hoyer and Office of Senate Majority Leader Charles E. Schumer
Chris Hale/CQ Roll Call

Updated 12/15/21

 Key dates: close of FY22 on Fri., Sept. 30th; midterm elections on Tues., Nov. 8th; proposed expiration of a CR to provide funding for FY23 at FY22 levels through Fri., Dec. 16th; and the first day of the 118th Congress on Tues., Jan. 3rd



CHIPS & Science Act – enacted August 9



Inflation Reduction Act – enacted August 16

Must-Pass Legislation (authorizations expiring on 9/30)

- FDA User Fees: 5-year clean reauthorization included in CR
- SBIR/STTR: 3-year, standalone reauthorization passed Senate on 9/20; House vote pending
- National Defense Authorization Act (annual)

Other Pending Legislation:

- Pandemic Preparedness & ARPA-H Authorization
- Telehealth continuation and expansion
- Clinical Trials access and inclusion

Delegation Visits NCI Frederick (July 22, 2022)

HHS Secretary Xavier Becerra, along with HHS Region 3 Director Dr. Ala Stanford, Senators Ben Cardin and Chris Van Hollen, and Rep. David Trone



From left to right: Carrie Bonomi, Dr. Melinda Hollingshead, Sec. Becerra, Rep. Trone, Dr. Stanford, Sen. Van Hollen, Sen. Cardin, Dr. Lowy, Kelly Dougherty






Malcolm Smith, MD, PhD

Associate Branch Chief,
Pediatrics in the Clinical Investigations Branch,
Division of Cancer Treatment and Diagnosis
(DCTD)



Nita Seibel, MD

Head,
Pediatric Solid Tumor Therapeutics in the Clinical
Investigations Branch, Cancer Therapy and
Evaluation Program, DCTD



Emily Tonorezos, MD, MPH

Director,
Office of Cancer Survivorship, Division of Cancer
Control and Population Sciences (DCCPS)



Sandra Mitchell, PhD, CRNP

Senior Scientist and Program Director,
Outcomes Research Branch in the Healthcare
Delivery Research Program, DCCPS



Danielle Dae, PhD

Program Director,
Genomic Epidemiology Branch, Epidemiology and
Genomics Research Program, DCCPS



Paul Jacobsen, PhD

Associate Director,
Healthcare Delivery Research Program, DCCPS

Additional Childhood Cancer Awareness Month Events

- **9/22:** 13th Annual Congressional Childhood Cancer Caucus Summit
- **9/23:** White House Cancer Moonshot Childhood Cancer Forum



Questions?

Holly.Gibbons@nih.gov

Maureen.Clark@nih.gov